Avid Bioservices Inc (CDMO)

[peregr]

Good point but let's take it one step further. The main difference is that this is a non-exclusive agreement. Astra (or Medimmune) will supply the durvalumab, then if consistent with the Mirati agreement, PPHM would negotiate a commercial license agreement. Exclusive would give more upfront payment but more collars on the licensing.

But, it would be nice to know from management the extent of the required dilution. Market could never absorb 200M shares on its own.